Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT04344769
Status
Recruiting
Apply to this trial

Conditions

  • Autosomal Dominant Polycystic Kidney Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - 30 Years
Healthy Volunteers
Accepted

Study Details

The purpose of this study is to characterize oxidative stress and the Nrf2 antioxidant response in early stages of Autosomal Dominant Polycystic Kidney Disease (ADPKD), while identifying candidate biomarkers.

Key Dates

Start date
Oct 4, 2019
Status verified
Jan 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
40 participants (estimated)

Arms

  • Arm: Patients with a previous diagnosis of ADPKD
    Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
  • Arm: Healthy individuals as controls
    Age and gender-matched healthy controls

Primary Outcome Measure

Assessment of Oxidative Status [ Time Frame: Baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in RochesterRochesterMinnesota55905-

Find similar trials in Rochester, MN

By research site
Mayo Clinic in Rochester· Rochester, MN

Related Studies